RHENIUM SULFIDE (RE2S7)
Infiltrative Breast Cancer
University Hospital, Strasbourg, FranceSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
59 Active assets in the Infiltrative Breast Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TAMOXIFEN University of California, San Francisco | Phase 4 | BBB |
Letrozole Emory University | Phase 4 | BBB |
Arimidex Jonsson Comprehensive Cancer Center | Phase 4 | BBB |
EXEMESTANE University of California, San Francisco | Phase 4 | BBB |
Carboplatin Baylor Breast Care Center | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →